At what enterprise value was HIPP TECHNOLOGY GROUP acquired in 2026?

During the acquisition of HIPP TECHNOLOGY GROUP by DEUTSCHE BETEILIGUNGS (DBAG) in 2026, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of HIPP TECHNOLOGY GROUP when it was acquired by DEUTSCHE BETEILIGUNGS (DBAG)?

The estimated EV/EBITDA multiple for HIPP TECHNOLOGY GROUP is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What was the revenue of HIPP TECHNOLOGY GROUP at the time of the deal?

The revenue of HIPP TECHNOLOGY GROUP at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of HIPP TECHNOLOGY GROUP during the acquisition?

HIPP TECHNOLOGY GROUP's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the HIPP TECHNOLOGY GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the HIPP TECHNOLOGY GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.dbag.com/newsroom/detail/deutsche-beteiligungs-ag-to-invest-in-leading-development-partner-and-medical-technology-contract-manufacturer-dbag-fund-viii-to-acquire-majority-stake-in-hipp-technology-group/

← DATABASE

Home Database Healthcare & PharmaHIPP TECHNOLOGY GROUP

03/2026

HIPP TECHNOLOGY GROUP acquired by DEUTSCHE BETEILIGUNGS (DBAG)

GERMANY Life Sciences / Medical Devices / Implants & Prosthetics EV 100M - 350M EUR

Context

Deutsche Beteiligungs AG (DBAG) has entered into a definitive agreement to acquire a majority stake in Hipp Technology Group, marking a significant entry into the medical contract manufacturing space. The transaction involves the acquisition of the majority interest previously held by the Swiss investment firm Endura Capital, with the financing provided by DBAG Fund VIII. A critical component of the deal structure is the retention of a significant minority stake by the founder and CEO, Markus Hipp, ensuring leadership continuity and alignment of interests. The strategic rationale for the acquisition is the transformation of Hipp Technology into a central platform for a broader international consolidation strategy. DBAG intends to leverage the company’s technical reputation and prime location in the Tuttlingen MedTech cluster to acquire complementary technologies and expand its global market presence. This "buy-and-build" approach is designed to capitalize on the increasing demand for specialized outsourcing in robotic surgery and orthopedics. The partnership will focus on scaling the current production capacity across its five sites while pursuing inorganic growth opportunities in Europe and beyond, professionalizing the group to serve a larger international client base of medical device manufacturers.

HIPP TECHNOLOGY GROUP, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Hipp Technology Group is a highly specialized development partner and Contract Development and Manufacturing Organization (CDMO) for the medical technology industry. The company focuses on the high-precision manufacturing of orthopedic implants, surgical instruments, and complex robotic surgery systems. Beyond its core MedTech focus, Hipp serves high-end industrial sectors including aerospace, semiconductors, and industrial automation. Operating across five sites with approximately 350 employees, the group is a critical "Tier 1" supplier to global medical device OEMs. Its business model relies on deep engineering expertise and the ability to manufacture life-critical components with extreme tolerances, positioning it as a key beneficiary of the trend toward minimally invasive surgery and robotic-assisted procedures.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2026	OURY MEDICAL	CÉFIMÉCA	FRANCE	Life Sciences	The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors
04/2026	FOR TALENTS / UI INVESTISSEMENT / GENEO	NEFTYS PHARMA	FRANCE	Life Sciences	In a structured minority growth equity transaction, specialized family capital investment firm For Talents has acquired a minority stake in Neftys Pharma. This strategic operation is executed alongside incumbent financial sponsors UI Investissement and GENEO Capital Entrepreneur, who are rolling over their investments after an initial four-year holding period
03/2026	SIPAREX	WINNCARE	FRANCE	Life Sciences	Siparex has reaffirmed its commitment to Winncare by leading a quaternary LBO to retain control of the medical device manufacturer. This transaction allows Siparex, which originally acquired the company in 2021 via its ETI 5 fund, to extend the maturity of its investment while slightly increasing its ownership stake alongside the management team led by President Laurent Faugères
03/2026	LONE STAR FUNDS	LONZA CHI	Switzerland	Life Sciences	Lone Star Funds has entered into a definitive agreement to acquire a majority stake in Lonza Group’s Capsules & Health Ingredients (CHI) division. Lonza will retain a 40% equity position in the newly independent business, ensuring industrial continuity and shared upside in the future growth of the platform
03/2026	RESONETICS	RESOLUTION MEDICAL	UNITED STATES	Life Sciences	The acquisition of Resolution Medical by Resonetics signifies a major step in the group’s expansion toward a comprehensive, full-lifecycle service model. The strategic rationale for this transaction centers on an "integrated-platform" maneuver, merging the target’s technical operational depth in biosimulation and cleanroom assembly with the acquirer’s established scale in laser-based component manufacturing and battery systems
02/2026	NORD HOLDING	HALLMARQ VETERINARY IMAGING	UNITED KINGDOM	Life Sciences	NORD Holding have acquired Hallmarq Veterinary Imaging from August Equity to merge it with German-based OR Technology. The transaction establishes a new, globally active imaging technology holding company in the veterinary sector
02/2026	CIMG	DAREN TECHNOLOGY	CHINA	Life Sciences	CIMG, through its subsidiary DZR, signed an agreement to acquire 100% of Daren Technology for approximately $40M in stock. The transaction features a highly structured Phased Payment consideration (6%, 14%, 28%, and 52%) released over 3
02/2026	IMA GROUP	PROSYS	IRELAND	Life Sciences	IMA Group acquired a majority stake in ProSys Sampling Systems Limited from its co-founder and Treysa Limited. The transaction is a core component of IMA's international growth strategy, aiming to strengthen its "IMA Life" division by integrating specialized containment and sampling expertise
02/2026	VIVO CAPITAL	DUTSCHER	FRANCE	Life Sciences	Vivo Capital acquired a majority stake in Dutscher from LBO France. LBO France had acquired the asset in July 2020 from Five Arrows (Rothschild) for an enterprise value of EUR100-150M (investing EUR60M in equity)
01/2026	FAGRON	UNIVERSITY COMPOUNDING PHARMACY (UCP)	UNITED STATES	Life Sciences	Fagron acquired 100% of University Compounding Pharmacy for an Enterprise granting to Fagron a stronghold in California (a high-barrier market) and adds complementary therapeutic expertise (Urology) to its existing US portfolio (which includes Anazao)

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HIPP TECHNOLOGY GROUP by DEUTSCHE BETEILIGUNGS (DBAG) are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: hipp technology group

Acquirer: deutsche beteiligungs (dbag)